Hi-Tech Pharmacal Co. (HITK) Misses Q3 EPS by 28c

Hi-Tech Pharmacal Co. (NASDAQ: HITK) reported Q3 EPS of $0.43, $0.28 worse than the analyst estimate of $0.71. Revenue for the quarter came in at $64.33 million versus the consensus estimate of $60.45 million.

For earnings history and earnings-related data on Hi-Tech Pharmacal Co. (HITK) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
• CVB Financial (CVBF) Tops Q1 EPS by 1c
• VIST Financial Corp. (VIST) Misses Q1 EPS by 19c